Spectral AI Reports Q1 2025 Earnings: Revenue Up, Net Income Turns Positive Amid Restructuring Challenges

Spectral AI, Inc. (NASDAQ: MDAI) reported its quarterly earnings on March 31, 2025, revealing significant changes amid ongoing growth and restructuring efforts in its operations. **Positive Aspects:** - **Revenue Growth:** Research and development revenue rose to $6.7 million in Q1 2025, a 6.0% increase from $6.3 million in Q1 2024. This reflects an uptick in activities under government contracts, particularly with the Biomedical Advanced Research and Development Authority (BARDA). - **Improved Gross Profit:** Gross profit increased to $3.2 million from $2.9 million year-over-year, resulting in a gross margin of 47.2%, compared to 46.6% in the previous year. - **Decrease in Operating Loss:** Operating loss narrowed to $896,000, an improvement from $2.1 million in the same quarter last year. - **Net Income:** The company recorded a net income of $2.9 million, a turnaround from a net loss of $3.2 million in Q1 2024, driven by gains in the fair value of warrant liabilities. - **Strong Liquidity Position:** Cash reserves increased to $14.1 million, a significant rise from $5.2 million a year earlier. **Negative Aspects:** - **High Operating Expenses:** General and administrative expenses remained elevated at $4.1 million, albeit down from $5.1 million in Q1 2024. This includes increased costs associated with operational expansions and administrative functions. - **Dependence on Government Contracts:** As of March 31, 2025, 95% of revenue was concentrated from one customer, a U.S. government agency, posing risks related to revenue sustainability if government funding fluctuates. - **Accumulated Deficit:** The company has an accumulated deficit of $45.3 million, although this is reduced from $48.2 million at the end of the previous quarter. **Key Statistics:** - **Revenue:** $6.7 million (up 6.0% Y/Y) - **Gross Profit:** $3.2 million (up 7.6% Y/Y) - **Operating Loss:** $(896,000) (improved from $(2.1 million) Y/Y) - **Net Income:** $2.9 million (up from $(3.2 million) Y/Y) - **Cash:** $14.1 million (up from $5.2 million Y/Y) - **Shares Outstanding:** 25,588,121 as of March 31, 2025 In summary, while the company shows promising growth with improved revenues and a solid cash position, issues regarding high operating expenses and heavy reliance on a single customer remain key challenges. Future performance will heavily depend on the successful commercialization of its DeepView System as it moves towards FDA approval and broader market engagement.